TY - JOUR
T1 - Advantages of a prospective multidisciplinary approach in transcatheter aortic valve implantation
T2 - Eight years of experience
AU - Costa, Cátia
AU - Teles, Rui Campante
AU - Brito, João
AU - Neves, José Pedro
AU - Gabriel, Henrique Mesquita
AU - Abecassis, Miguel
AU - Ribeiras, Regina
AU - Abecasis, João
AU - Nolasco, Tiago
AU - Furstenau, Maria da Conceição
AU - Vale, Nélson
AU - Tralhão, António
AU - Madeira, Sérgio
AU - Mesquita, João
AU - Saraiva, Carla
AU - Calé, Rita
AU - Almeida, Manuel
AU - Aleixo, Ana
AU - Mendes, Miguel
N1 - Copyright © 2017 Sociedade Portuguesa de Cardiologia. Publicado por Elsevier España, S.L.U. All rights reserved.
PY - 2017/11
Y1 - 2017/11
N2 - INTRODUCTION: Aortic stenosis is the most prevalent type of valvular disease in Europe. Surgical aortic valve replacement (SAVR) is the standard therapy, while transcatheter aortic valve implantation (TAVI) is an alternative in patients at unacceptably high surgical risk. Assessment by a heart team is recommended by the guidelines but there is little published evidence on this subject. The purpose of this paper is to describe the experience of a multidisciplinary TAVI program that began in 2008.METHODS: The heart team prospectively assessed 473 patients using a standardized approach. A total of 214 patients were selected for TAVI and 80 for SAVR. Demographic, clinical and procedural characteristics and long-term success rates were compared between the groups.RESULTS: TAVI patients were older than the SAVR group (median 83 vs. 81 years), and had higher surgical risk scores (median EuroSCORE II 5.3 vs. 3.6% and Society of Thoracic Surgeons score 5.1 vs. 3.1%), as did the patients under medical treatment only. These scores were unable to assess multiple comorbidities. Patients' outcomes were different between the three groups (mortality with SAVR 25% vs. TAVI 37.6% vs. conservative therapy 57.6%, p=0.001).CONCLUSIONS: The heart team program was able to select candidates appropriately for TAVI, SAVR and conservative treatment, taking into account the risk of both invasive treatments. The use of a prospective standardized heart team approach is recommended, but requires continuous monitoring to ensure effectiveness in a timely manner.
AB - INTRODUCTION: Aortic stenosis is the most prevalent type of valvular disease in Europe. Surgical aortic valve replacement (SAVR) is the standard therapy, while transcatheter aortic valve implantation (TAVI) is an alternative in patients at unacceptably high surgical risk. Assessment by a heart team is recommended by the guidelines but there is little published evidence on this subject. The purpose of this paper is to describe the experience of a multidisciplinary TAVI program that began in 2008.METHODS: The heart team prospectively assessed 473 patients using a standardized approach. A total of 214 patients were selected for TAVI and 80 for SAVR. Demographic, clinical and procedural characteristics and long-term success rates were compared between the groups.RESULTS: TAVI patients were older than the SAVR group (median 83 vs. 81 years), and had higher surgical risk scores (median EuroSCORE II 5.3 vs. 3.6% and Society of Thoracic Surgeons score 5.1 vs. 3.1%), as did the patients under medical treatment only. These scores were unable to assess multiple comorbidities. Patients' outcomes were different between the three groups (mortality with SAVR 25% vs. TAVI 37.6% vs. conservative therapy 57.6%, p=0.001).CONCLUSIONS: The heart team program was able to select candidates appropriately for TAVI, SAVR and conservative treatment, taking into account the risk of both invasive treatments. The use of a prospective standardized heart team approach is recommended, but requires continuous monitoring to ensure effectiveness in a timely manner.
KW - Surgical aortic valve replacement
KW - Transcatheter aortic valve implantation
KW - Válvula aórtica percutânea
KW - Estenose aórtica grave
KW - Heart Team
KW - Severe aortic stenosis
KW - Standardization
KW - Standardização
KW - Substituição valvular aórtica cirúrgica
U2 - 10.1016/j.repc.2016.11.015
DO - 10.1016/j.repc.2016.11.015
M3 - Article
C2 - 29153618
VL - 36
SP - 809
EP - 818
JO - Revista Portuguesa de Cardiologia
JF - Revista Portuguesa de Cardiologia
SN - 0304-4750
IS - 11
ER -